One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.
But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.
Best stocks to buy for the week ending Sept. 19, 2014:Last week, U.S. market history was made when Alibaba debuted as the biggest IPO of all time. While we like BABA stock, it's not the only way to profit.
You can find all of last week's recommendations here in our newest list of the best stocks to buy now.
Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.
Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.
For investors looking for the best penny stocks to buy, the biotech sector offers some of the best investment opportunities on the market.
Despite the fact that biotech stocks have been up and down in 2014, Money Morning's Bioscience Investment Specialist Ernie Tremblay sees great profit opportunities for the rest of 2014.
Ask any bioscience researcher about leading trends in medical science, and at some point, you're likely to hear a lot of enthusiasm around the phrase personalized medicine.
That's treatment based on the individual's particular disease state, risk factors, and most importantly, genetic profile. And it's already yielding unheard-of profits for traders and investors.
As scientists reach the discovery limits of "one-size-fits-all" drugs and the ailments that respond to them, such as infections and circulatory diseases, they find themselves up against tougher, wilier, more intractable challenges... Full Story
Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.
The stock is up 14% in the last month and is still showing bullish signs.
One of yesterday's (Wednesday) biggest stock gainers, Cerulean Pharma Inc. (Nasdaq: CERU), is a biotech company that posted a 30.6% gain by day's end.
This comes at a time when short sellers are adding to their positions, waiting for a downfall of biotech, and even the country's head central banker Janet Yellen has little faith in the sector. Biotech has been on a rally over the last year, a rally that a lot of traders feel has run its course.
Intercept Pharmaceuticals (Nasdaq: ICPT) stock surged 45% today (Tuesday) to a new 52-week high of $349.08 after the company reported Q2 results and provided promising updates on several of its key drugs.
Updated August 14, 2014: Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor - the world's best-selling drug of all time - causes type-2 diabetes in women.
"This will be a huge overhang on Pfizer stock," Money Morning Capital Wave Strategist Shah Gilani said. "Investors have to watch developments closely."
With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer's patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.
Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers. Here’s why this hot biotech stock is just getting started.
This is not a misprint: Puma Biotechnology Inc. (NYSE: PBYI) stock surged nearly 300%, or $176.63, to an all-time high of $234.99 intraday Wednesday.
Founded in 2010 and based in Los Angeles, Puma doesn't have a single drug yet on the market.
Stock market today, July 16, 2014: U.S. stock markets slacked on Tuesday after statements by U.S. Federal Reserve Chair Janet Yellen in front of the Senate Banking Committee indicated that some sectors might be overvalued. Biotech and social media shares slumped in the afternoon. The iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB) slumped by more than 2.5% after Yellen's testimony.
Stock Market Today, July 15, 2014: U.S. markets slacked on Tuesday after statements by U.S. Federal Reserve Chair Janet Yellen in front of the Senate Banking Committee indicated that some sectors might be overvalued. Biotech and social media shares slumped in the afternoon. The iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB) slumped by more than 2.5% after Yellen's testimony.
Last week, we covered a "catalyst" that could spark a share-price rally for what is already one of the best stocks to buy, three recommendations to take advantage of rising oil prices, and a way to tap into big profits in an "other" bioscience niche that is less risky but highly lucrative.